KR20240015622A - 심장 근절 억제제 - Google Patents

심장 근절 억제제 Download PDF

Info

Publication number
KR20240015622A
KR20240015622A KR1020237033052A KR20237033052A KR20240015622A KR 20240015622 A KR20240015622 A KR 20240015622A KR 1020237033052 A KR1020237033052 A KR 1020237033052A KR 20237033052 A KR20237033052 A KR 20237033052A KR 20240015622 A KR20240015622 A KR 20240015622A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
tautomer
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237033052A
Other languages
English (en)
Korean (ko)
Inventor
브래들리 피. 모르간
치위안 추앙
루크 더블유. 애쉬크라프트
저스틴 호
알프레도 가르시아
Original Assignee
싸이토키네틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 싸이토키네틱스, 인코포레이티드 filed Critical 싸이토키네틱스, 인코포레이티드
Publication of KR20240015622A publication Critical patent/KR20240015622A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237033052A 2021-03-04 2022-03-03 심장 근절 억제제 Pending KR20240015622A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163156853P 2021-03-04 2021-03-04
US63/156,853 2021-03-04
PCT/US2022/018725 WO2022187501A1 (en) 2021-03-04 2022-03-03 Cardiac sarcomere inhibitors

Publications (1)

Publication Number Publication Date
KR20240015622A true KR20240015622A (ko) 2024-02-05

Family

ID=80937093

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237033052A Pending KR20240015622A (ko) 2021-03-04 2022-03-03 심장 근절 억제제

Country Status (14)

Country Link
US (2) US11919909B2 (https=)
EP (1) EP4301760A1 (https=)
JP (1) JP7850737B2 (https=)
KR (1) KR20240015622A (https=)
CN (1) CN117083275A (https=)
AR (1) AR125026A1 (https=)
AU (1) AU2022229390A1 (https=)
BR (1) BR112023017461A2 (https=)
CA (1) CA3209557A1 (https=)
CL (2) CL2023002616A1 (https=)
IL (1) IL305628A (https=)
MX (1) MX2023010125A (https=)
TW (1) TW202302594A (https=)
WO (1) WO2022187501A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
MA53491A (fr) * 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
CN117083275A (zh) 2021-03-04 2023-11-17 赛特凯恩蒂克公司 心脏肌节抑制剂
RS67793B1 (sr) * 2022-09-02 2026-03-31 Cytokinetics Inc Kristalni oblici 5-(3,4-difluorbenzil)-8-((1r,4r)-4-metilcikloheksil)-6,9-diokso-2,5,8-triazapiro[3.5]nonan-2-karbaldehida

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US5919785A (en) 1996-04-03 1999-07-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU2002365057A1 (en) 2001-12-21 2003-07-30 Cytokinetics, Inc. Compositions and methods for treating heart failure
ATE552236T1 (de) 2003-01-14 2012-04-15 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von herzinsuffizienz
EP1605752B1 (en) 2003-03-27 2011-09-14 Cytokinetics, Inc. Sulfonamides for the treatment of congestive heart failure, their compositions and uses.
EP1621540A4 (en) 2003-04-21 2008-07-23 Ono Pharmaceutical Co HETEROCYCLIC COMPOUNDS CONTAINING NITROGEN AND USE THEREOF
ES2522579T3 (es) 2004-06-17 2014-11-17 Cytokinetics, Inc. Compuestos, composiciones y métodos
JP2008521900A (ja) 2004-11-30 2008-06-26 アムジエン・インコーポレーテツド キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
TW200718692A (en) 2005-04-22 2007-05-16 Wyeth Corp Dihydrobenzofuran derivatives and uses thereof
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
RU2318818C1 (ru) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
SA08290245B1 (ar) 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
US20090192168A1 (en) 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
NZ596302A (en) 2009-05-15 2014-01-31 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
US8592426B2 (en) 2011-01-24 2013-11-26 Hoffmann—La Roche Inc. Aryl-benzocycloalkyl amide derivatives
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
US9409917B2 (en) 2012-01-20 2016-08-09 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
SMT202000071T1 (it) 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
US9199945B2 (en) 2013-06-21 2015-12-01 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
US9663516B2 (en) 2014-12-18 2017-05-30 MyoKardia, Inc. Bicyclic-pyrimidinedione compounds
CN104539229A (zh) 2014-12-26 2015-04-22 金海新源电气江苏有限公司 一种太阳能光伏支架
EP4234017B1 (en) 2015-01-22 2026-04-15 MyoKardia, Inc. Preparation of 4-methylsulfonyl-substituted piperidine urea compounds useful for the treatment of cardiac disorders such as dilated cardiomyopathy (dcm)
JP2019507110A (ja) 2015-12-17 2019-03-14 シンジェンタ パーティシペーションズ アーゲー 殺微生物性オキサジアゾール誘導体
CN108368098B (zh) 2015-12-18 2022-01-28 先正达参股股份有限公司 杀微生物的噁二唑衍生物
CA3022432A1 (en) 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Sigma receptor binders
WO2017222951A1 (en) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
JP6681517B2 (ja) 2016-09-27 2020-04-15 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ｍＧｌｕＲ２陰性アロステリック調節剤としてのクロマン、イソクロマン及びジヒドロイソベンゾフラン誘導体、組成物、及びそれらの使用
WO2018089433A1 (en) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL mTORC INHIBITORS AND USES THEREOF
WO2018156883A1 (en) 2017-02-23 2018-08-30 Board Of Regents, The University Of Texas System Methods of treatment for cancer, sterol homeostasis, and neurological diseases
CA3071948A1 (en) 2017-08-04 2019-02-07 MyoKardia, Inc. Mavacamten for use in the treatment of hypertrophic cardiomyopathy
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
MX2021001380A (es) 2018-08-31 2021-05-27 Xenon Pharmaceuticals Inc Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos.
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
EA202191152A1 (ru) 2018-10-29 2022-01-19 Миокардиа, Инк. Тетрагидропиран (thp)-замещенные бициклические соединения пиримидиндиона
RS65302B1 (sr) 2019-07-17 2024-04-30 Cytokinetics Inc Oralne formulacije inhibitora srčanog sarkomera
EP3999180B1 (en) 2019-07-17 2024-05-08 Cytokinetics, Inc. Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
EP4054588A4 (en) 2019-11-10 2023-12-13 MyoKardia, Inc. Methods of treatment with myosin modulator
MX2023002024A (es) 2020-08-28 2023-05-10 Myokardia Inc Métodos de tratamiento con modulador de miosina.
CN114456163B (zh) 2020-11-09 2023-08-11 江苏恒瑞医药股份有限公司 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114516843B (zh) 2020-11-19 2024-10-22 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
WO2022105852A1 (zh) 2020-11-20 2022-05-27 江苏恒瑞医药股份有限公司 三嗪二酮类衍生物、其制备方法及其在医药上的应用
CN116507621B (zh) 2020-11-24 2025-10-17 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114539257B (zh) 2020-11-24 2023-08-11 江苏恒瑞医药股份有限公司 嘧啶二酮类螺环衍生物、其制备方法及其在医药上的应用
CN114539229B (zh) 2020-11-24 2024-10-22 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
TWI820622B (zh) 2021-03-04 2023-11-01 美商美國禮來大藥廠 Fgfr3抑制劑化合物
CN117083275A (zh) 2021-03-04 2023-11-17 赛特凯恩蒂克公司 心脏肌节抑制剂
RS67793B1 (sr) 2022-09-02 2026-03-31 Cytokinetics Inc Kristalni oblici 5-(3,4-difluorbenzil)-8-((1r,4r)-4-metilcikloheksil)-6,9-diokso-2,5,8-triazapiro[3.5]nonan-2-karbaldehida

Also Published As

Publication number Publication date
US11919909B2 (en) 2024-03-05
JP7850737B2 (ja) 2026-04-23
US20220306642A1 (en) 2022-09-29
CL2024001620A1 (es) 2024-11-04
MX2023010125A (es) 2023-09-11
WO2022187501A1 (en) 2022-09-09
CN117083275A (zh) 2023-11-17
IL305628A (en) 2023-11-01
EP4301760A1 (en) 2024-01-10
CA3209557A1 (en) 2022-09-09
CL2023002616A1 (es) 2024-02-02
JP2024508526A (ja) 2024-02-27
AU2022229390A1 (en) 2023-09-21
US12286437B2 (en) 2025-04-29
TW202302594A (zh) 2023-01-16
BR112023017461A2 (pt) 2023-09-26
AR125026A1 (es) 2023-05-31
US20240309011A1 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
KR20240015622A (ko) 심장 근절 억제제
JP7825650B2 (ja) 心筋サルコメア阻害剤
JP7438148B2 (ja) 心臓サルコメア阻害剤
JP7094989B2 (ja) シクロプロピルウレアホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト
US12187712B2 (en) Cardiac sarcomere inhibitors
JP6948322B2 (ja) Ａｐｊ受容体のａｐｊアゴニストとしてのヘテロアリールヒドロキシピリミジノン
CN113811300A (zh) Tead转录因子的新型小分子抑制剂
KR102433280B1 (ko) Apj 효능제로서의 6-히드록시-4-옥소-1,4-디히드로피리미딘-5-카르복스아미드
JP2014510154A (ja) 神経変性疾患の治療方法及び治療用組成物
WO2019101086A1 (zh) 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
US20110243844A1 (en) Sulfonamide derivative metabotropic glutamate r4 ligands
JP7301758B2 (ja) 縮合二環式化合物、その組成物及び応用
US20110318266A1 (en) Phthalimide derivative metabotropic glutamate r4 ligands
EP4581034B1 (en) Crystalline forms of 5-(3,4-difluorobenzyl)-8-((1r,4r)-4-methylcyclohexyl)-6,9-dioxo-2,5,8-triazaspiro[3.5]nonane-2-carbaldehyde
WO2021127459A1 (en) Gpr139 receptor modulators
HK40102197A (zh) 心脏肌节抑制剂
EA048764B1 (ru) Ингибиторы саркомеров сердца
JP2000351773A (ja) フラン誘導体からなる医薬
RU2811745C1 (ru) Ингибиторы альдостеронсинтазы (CYP11B2) человека
HK40125944A (zh) 5-(3，4-二氟苄基)-8-((1r，4r)-4-甲基环己基)-6，9-二氧代基-2，5，8-三氮杂螺[3.5]壬烷-2-甲醛的结晶形式
EA050143B1 (ru) Ингибиторы альдостеронсинтазы человека (cyp11b2)
WO2022037601A1 (zh) 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在制备治疗癌症和炎症药物中的用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15 Change to inventor requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R15-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16 Change to inventor recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R16-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000